strontium(2+)/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases WOMAC pain subscale
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Treatment with strontium ranelate 2 g/day was associated with significantly lower WOMAC total score (p=0.045) and pain subscore (p=0.028), and a trend toward lower physical function subscore (p=0.099) and global knee pain (p=0.065) (table 2).”
Quoted verbatim from Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.. - Study
- RCT
- Dose
- strontium ranelate 2 g/day
- Population
- Outpatients aged 50 or over with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3), intention-to-treat population; 2 g/day dose stratum only (the 1 g/day dose showed no significant reduction)
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.2013PMID:23117245Permalink
Keep reading
- Everything the graph holds on strontium(2+)
- Every compound studied against WOMAC pain subscale
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5N0YM2ZYQ6J2S11CYATAQ92